Trade Names:Cefzil- Tablets 250 mg (as anhydrous)- Tablets 500 mg (as anhydrous)- Powder for oral suspension 125 mg per 5 mL (as anhydrous). Contains sucrose, aspartame, 28 mg per 5 mL phenylalanine- Powder for oral suspension 250 mg per 5 mL (as anhydrous). Contains sucrose, aspartame, 28 mg per 5 mL phenylalanineRAN-Cefprozil (Canada)
Inhibits mucopeptide synthesis in bacterial cell wall.
Cefprozil is about 95% absorbed. Food increased T max 0.25 to 0.75 h. T max is about 1.5 h. C max is 18.3 mcg/mL.
Vd is about 0.23 L/kg. Cefprozil is about 36% protein bound.
Plasma t ½ is 1.3 h. Total body Cl is about 3 mL/min/kg. Renal Cl is about 2.3 mL/min/kg. The 8-h urinary excretion accounted for 54% to 62% of the dose.
The t ½ may be up to 5.2 h.Hepatic Function Impairment
The t ½ increases to about 2 h.Elderly
AUC is about 35% to 60% higher.
Treatment of infections of skin and skin structures, bronchitis, pharyngitis, tonsillitis, and otitis media caused by susceptible strains of specific microorganisms.
Hypersensitivity to cephalosporins.
PO 250 to 500 mg every 12 to 24 h.Children 6 mo to 12 yr of age
PO 7.5 to 15 mg/kg every 12 h.
May be given without regard to meals. Administer with food or milk if GI upset occurs. Food slows but does not decrease absorption.
After reconstitution, oral suspension must be refrigerated. Solution may be stored for up to 14 days in refrigerator. Do not freeze. Shake well before use.Tablets
Store tablets at room temperature.
Inhibition of renal excretion of cefprozil.
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets but not with enzyme-based tests (eg, Clinistix , Tes-tape ); false-positive test results for proteinuria with acid and denaturization-precipitation tests; false-positive direct Coombs test result in certain patients (eg, those with azotemia); false elevations in urinary 17-ketosteroid values.
Headache, dizziness; fatigue; paresthesia; confusion; nervousness; sleeplessness; insomnia.
Nausea; vomiting; diarrhea; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
Genital pruritus; vaginitis; renal function impairment.
Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage.
Hepatic function impairment; cholestatic jaundice; abnormal LFT results.
Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness–like reactions (eg, skin rashes, polyarthritis, arthralgia, fever).
MonitorResponse to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not appear to improve or worsens.Adverse reactions
Monitor patient for GI, DERM, and general body adverse reactions, and signs of superinfection. Inform health care provider if noted and significant. Immediately report severe diarrhea, diarrhea containing blood or pus, or severe abdominal cramping.
Category B .
Excreted in breast milk.
Safety and efficacy in children younger than 6 mo of age not established.
Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients because of possible cross-reactivity.
Use drug with caution in patients with renal function impairment. Dosage adjustment based on renal function may be required.
May result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Consider in patients in whom diarrhea develops.
Copyright © 2009 Wolters Kluwer Health.